This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Nurix Therapeutics, Inc. (NRIX) Loses -19.36% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strategic executions on the United States and the international fronts are likely to drive Walgreens (WBA) Q4 revenues.
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nurix Therapeutics, Inc. (NRIX) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Nurix Therapeutics, Inc. (NRIX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 215.32%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 215.3% upside potential for Nurix Therapeutics, Inc. (NRIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Nurix (NRIX) Stock Increases 9% in a Month: Here's Why
by Zacks Equity Research
The upside in Nurix's (NRIX) shares can be attributed to the company's recently signed collaboration with Seagen (SGEN) to develop a new class of medicines for cancer.
Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wall Street Analysts Believe Nurix Therapeutics, Inc. (NRIX) Could Rally 195.93%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 195.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 28.57% and 39.67%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?
Swedish Orphan Biovitrum (BIOVF) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Swedish Orphan Biovitrum (BIOVF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Nurix Therapeutics, Inc. (NRIX) Have the Potential to Rally 192.09% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 192.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)
by Zacks Equity Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Wall Street Analysts Predict a 233.33% Upside in Nurix Therapeutics, Inc. (NRIX): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 233.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Much Upside is Left in Nurix Therapeutics, Inc. (NRIX)? Wall Street Analysts Think 134.94%
by Zacks Equity Research
The consensus price target hints at a 134.9% upside potential for Nurix Therapeutics, Inc. (NRIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 16.67% and 20.91%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Nurix Therapeutics, Inc. (NRIX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study
by Zacks Equity Research
Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.
Gilead (GILD) Exercises Option to License Nurix's Candidate
by Zacks Equity Research
Gilead (GILD) exercises an option under its collaboration agreement with Nurix to license the latter???s investigational targeted protein degrader molecule NX 0479.
Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead
by Zacks Equity Research
Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.
Strength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump Turn into More Strength?
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -27.94% and 65.46%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
Bears are Losing Control Over Nurix Therapeutics, Inc. (NRIX), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.